All | Men | Women | |||||||
Time period | MI | PY | IR (95% CI) | MI | PY | IR (95% CI) | MI | PY | IR (95% CI) |
First month post-GCA diagnosis | |||||||||
0–1 month | 5 | 92.4 | 54.1 (6.7 to 101.5) | 1 | 26.17 | 38.2 (0 to 113.1) | 4 | 66.27 | 60.4 (1.2 to 119.5) |
First year post-GCA diagnosis | |||||||||
0–3 months | 13 | 274.4 | 47.4 (21.6 to 73.1) | 5 | 77.4 | 64.6 (8 to 121.2) | 8 | 197.1 | 40.6 (12.5 to 68.7) |
4–6 months | 2 | 268.28 | 7.5 (0 to 17.8) | 0 | 75.4 | 0 | 2 | 192.9 | 10.4 (0 to 24.7) |
7–9 months | 3 | 263.8 | 11.4 (0 to 24.2) | 1 | 73.9 | 13.5 (0 to 40.1) | 2 | 189.9 | 10.5 (0 to 25.1) |
10–12 months | 3 | 274.7 | 10.9 (0 to 23.3) | 2 | 77.2 | 25.9 (0 to 61.8) | 1 | 197.5 | 5.1 (0 to 15) |
0–12 months | 21 | 1081.2 | 19.4 (11.1 to 27.7) | 8 | 303.9 | 26.3 (8.1 to 44.6) | 13 | 777.4 | 16.7 (7.6 to 25.8) |
Year 2 to end of follow-up | |||||||||
13–24 months | 10 | 1004.1 | 10 (3.8 to 16.1) | 5 | 277.6 | 18 (2.2 to 33.8) | 5 | 726.5 | 6.9 (0.8 to 12.9) |
Years 3–5 | 34 | 2428.8 | 14 (9.3 to 18.7) | 11 | 606.8 | 18.1 (7.4 to 28.8) | 23 | 1822 | 12.6 (7.5 to 17.8) |
Years 6–10 | 25 | 2361 | 10.6 (6.4 to 14.7) | 7 | 553.9 | 12.6 (3.3 to 22) | 18 | 1807.2 | 10 (5.4 to 14.6) |
Years 11 to end of follow-up | 12 | 1082.5 | 11.1 (4.8 to 17.4) | 3 | 278.9 | 10.8 (0 to 22.9) | 9 | 803.6 | 11.2 (3.9 to 18.5) |
Entire follow-up period | |||||||||
Entire follow-up | 102 | 7957.5 | 12.8 (10.3 to 15.3) | 34 | 2021 | 16.8 (11.2 to 22.5) | 68 | 5936.5 | 11.5 (8.7 to 14.2) |
*Per 1000 PY.
IR, incidence rate; PY, person-years.